Is Hemostemix’s stem cell therapy Your Fountain of Youth?
|
Issuer: Goldinvest Consulting GmbH
/ Key word(s): Miscellaneous/Product Launch
Canadian biotech company Hemostemix (TSXV:HEM; FRA:2VF0) has confidently secured the registered trademark "your fountain of youth" (TM)[1]"). But what sounds like science fiction or mere marketing is not. Rather, this promise gets to the heart of Hemostemix's stem cell therapy: the company has treated heart patients, patients with diabetic foot and patients with vascular dementia under scientific supervision with statistically proven success! Today, all those who need stem cells to regenerate their circulatory system can receive them. Soon, the company predicts, it will offer its therapy as naturally and regularly as you would an annual visit to the spa. Who wouldn't want to maintain the clear mind and quality of life we enjoy in our 40s and 50s well into our 80s and 90s? Read the full article now: Hemostemix' rejuvenation therapy saves limbs, heals ulcers and ends pain
Disclaimer: GOLDINVEST Consulting GmbH offers editors, agencies and companies the opportunity to publish comments, analyses and news on https://biotechinvest.de/. This content is intended solely for the information of readers and does not constitute a call to action; neither explicitly nor implicitly are they to be understood as a guarantee of possible price developments. Furthermore, they are in no way a substitute for individual expert investment advice and do not constitute an offer to sell the share(s) discussed or a solicitation to buy or sell securities. It is expressly not a financial analysis, but rather an advertising/journalistic text. Readers who make investment decisions or carry out transactions on the basis of the information provided here do so exclusively at their own risk. There is no contractual relationship between GOLDINVEST Consulting GmbH and its readers or the users of its offers, as our information relates only to the company and not to the reader's investment decision. The acquisition of securities is associated with high risks, which can lead to a total loss of the capital invested. The information published by GOLDINVEST Consulting GmbH and its authors is based on careful research. Nevertheless, any liability for financial losses or the guarantee for the topicality, correctness, appropriateness and completeness of the articles offered here is expressly excluded. Please also note our terms of use. According to §34b WpHG (Germany) and §48f Abs. 5 BörseG (Austria) we point out that GOLDINVEST Consulting GmbH, partners, authors, customers or employees of GOLDINVEST Consulting GmbH hold shares of Hemostemix Inc. and therefore a conflict of interest exists. GOLDINVEST Consulting GmbH also reserves the right to buy or sell shares in the company at any time. Under certain circumstances, this may influence the respective share price of the company. GOLDINVEST Consulting GmbH is currently in a paid contractual relationship with the company, which is reported on the GOLDINVEST Consulting GmbH website as well as in social media, on partner sites or in e-mail messages. This is a clear conflict of interest. The above references to existing conflicts of interest apply to all types and forms of publication that GOLDINVEST Consulting GmbH uses for publications about Hemostemix Inc. Furthermore, we cannot rule out the possibility that other market letters, media or research companies may discuss the stocks we cover during the same period. Therefore, there may be a symmetrical formation of information and opinions during this period. No guarantee can be given for the accuracy of the prices quoted in the publication.
Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Goldinvest Consulting GmbH |
| Kellinghusenstr. 15 | |
| 20249 Hamburg | |
| Germany | |
| Internet: | www.biotechinvest.de |
| EQS News ID: | 2068307 |
| End of News | EQS News Service |
|
|
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.